HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VVOS
Vivos Therapeutics, Inc.
VVOS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VVOS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VVOS's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VVOS PE Valuation
VVOS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VVOS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect VVOS's losses to grow, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
VVOS has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus VVOS down 117%.
VVOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$10.12 | +$2.88 |
| Q2 2024 | -$11.47 | +$6.28 |
| Q1 2024 | -$15.37 | +$6.13 |
| Q4 2023 | -$15.49 | +$10.51 |
| Q3 2023 | -$13.00 | +$16.00 |
| Q2 2023 | -$17.75 | +$11.25 |
| Q1 2023 | -$21.50 | +$4.00 |
| Q4 2022 | -$26.00 | -$2.00 |
VVOS is still losing money, but far less than before: $1.90 per share over the past year, against $29.00 at its worst in mid-2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VVOS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over VVOS on profitability, with a higher operating margin.
VVOS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.2M | +35% |
| Q1 2026 | $5.1M | +70% |
| Q4 2025 | $3.8M | +3.4% |
| Q3 2025 | $6.8M | +76% |
| Q2 2025 | $3.8M | -5.8% |
| Q1 2025 | $3M | -12% |
| Q4 2024 | $3.7M | +14% |
| Q3 2024 | $3.9M | +17% |
VVOS's revenue has grown year over year for four quarters in a row: $5M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | +34 points |
| Q1 2026 | -129% | +1.2 points |
| Q4 2025 | -167% | -91 points |
| Q3 2025 | -70% | -1.3 points |
| Q2 2025 | -127% | -80 points |
| Q1 2025 | -130% | -19 points |
| Q4 2024 | -76% | +56 points |
| Q3 2024 | -69% | +37 points |
VVOS's operating margin was −94% last quarter, up 34 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VVOS on cash generation, producing positive trailing cash flow while its opponent burns cash.
VVOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.6M | +$701K |
| Q1 2026 | -$6M | -$2.1M |
| Q4 2025 | -$5.3M | -$2.2M |
| Q3 2025 | -$4.1M | +$301K |
| Q2 2025 | -$4.3M | -$1.2M |
| Q1 2025 | -$3.9M | -$1.3M |
| Q4 2024 | -$3.1M | -$192K |
| Q3 2024 | -$4.4M | -$1.4M |
VVOS has burned cash in almost every quarter: −$19M over the past year, against −$16M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VVOS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VVOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +3M shares |
| 1 year | +106% | +9.1M shares |
| 3 years | +1982% | +16.8M shares |
| 5 years | +3457% | +17.2M shares |
VVOS has 18M diluted shares, up 106% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2M |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $150,000 |
| Q4 2019 | — |
| Q3 2019 | $50,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VVOS Net Leverage
VVOS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VVOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.8 | Oversold |
| Stochastic | 1.3 | Oversold |
VVOS's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VVOS PE vs Healthcare Sector
VVOS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VVOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.13 | 23% below |
| 20 week MA | $0.24 | 58% below |
| 50 week MA | $0.88 | 89% below |
| 100 week MA | $2.22 | 95% below |
| 200 week MA | $4.63 | 98% below |
VVOS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over VVOS on returns for 2026, with the stronger performance.
VVOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $224.8 | $184.5 | -18% |
| 2021 | $184.5 | $68.5 | -63% |
| 2022 | $68.5 | $11.9 | -83% |
| 2023 | $11.9 | $12.4 | +4.3% |
| 2024 | $12.4 | $4.65 | -63% |
| 2025 | $4.65 | $2.03 | -56% |
| 2026 YTD | $2.03 | $0.10 | -95% |
VVOS has finished lower in five of the last six years. It's down 95% so far in 2026.